Ondansetron B. Braun (Ondansetron)

Ondansetron is a 5‑HT3 receptor antagonist used to control nausea and vomiting associated with specific medical interventions.

• Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy.
• Radiotherapy‑induced nausea and vomiting: helps prevent nausea and vomiting caused by radiation treatment.
• Postoperative nausea and vomiting: decreases incidence of nausea and vomiting after surgical procedures.

• Ondansetron selectively blocks serotonin (5‑HT3) receptors located in the chemoreceptor trigger zone of the brain and on vagal afferents of the gastrointestinal tract. By preventing serotonin from binding to these receptors, it interrupts the neural signaling pathway that initiates the vomiting reflex, thereby reducing nausea and vomiting associated with chemotherapy, radiotherapy, and surgery.

Common Side Effects

• Headache: mild to moderate pain often reported after administration.
• Constipation: reduced bowel motility leading to infrequent stools.
• Dizziness: transient sensation of light‑headedness.
• Fatigue: feeling unusually tired or weak.
• Injection site reactions: pain, erythema or swelling at the site of administration.
• Diarrhoea: loose stools occurring in some patients.

Serious or Rare Side Effects

• QT interval prolongation: may predispose to cardiac arrhythmias.
• Severe allergic reaction: anaphylaxis, rash, or angio‑edema.
• Serotonin syndrome: rare but potentially life‑threatening when combined with other serotonergic agents.
• Hypotension: sudden drop in blood pressure.
• Hepatic enzyme elevation: abnormal liver function tests.
• Neuroleptic malignant‑like syndrome: extremely rare neuromuscular disorder.

Before using Ondansetron B. Braun, consider the following precautions:

• Cardiac risk assessment: evaluate baseline ECG and electrolyte status to mitigate QT‑prolongation risk.
• Concomitant QT‑prolonging drugs: avoid or monitor closely when used with other agents that affect cardiac repolarisation.
• Hepatic impairment: use with caution in patients with moderate to severe liver dysfunction.
• Renal impairment: dose adjustment may be required in severe renal failure.
• Pregnancy and lactation: weigh potential benefits against unknown risks; consult obstetric guidance.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with several medications; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid)

• Apomorphine: concurrent use can cause severe hypotension and loss of consciousness.
• Other QT‑prolonging agents (e.g., quinidine, sotalol): may significantly increase risk of cardiac arrhythmias.
• Serotonergic drugs (e.g., SSRIs, MAO inhibitors): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Carbamazepine: induces metabolism, potentially reducing ondansetron efficacy.
• Erythromycin and other macrolide antibiotics: may increase plasma concentrations of ondansetron.
• Ketoconazole and other strong CYP3A4 inhibitors: can elevate ondansetron levels.
• Digoxin: may experience modest increase in serum digoxin concentrations.